FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Cholangiocarcinoma

Therapeutic area intelligence for Cholangiocarcinoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Durvalumab →

Recent signals(1)

ClinicalAugust 16, 2026

Phase II Trial of Durvalumab with Chemotherapy for High-Risk Resectable Cholangiocarcinoma

The National Cancer Institute is sponsoring a phase II trial to assess the efficacy of durvalumab in combination with gemcitabine and cisplatin for patients with high-risk resectable cholangiocarcinoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Cholangiocarcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.